All In Biotech

Drug Trial Radar · NCT04188379

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX 113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia

Last checked: Nov 20, 2026Latest source record: Mar 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 131 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

131

Actual

Start

Dec 16, 2019

Primary completion

Feb 3, 2022

Study completion Feb 3, 2022

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
Dec 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in participants with primary ITP.

Conditions

  • Primary Immune Thrombocytopenia

Interventions

  • efgartigimodBiological

    Intravenous infusion of efgartigimod

  • PlaceboOther

    Intravenous infusion of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Chronic ITP With a Sustained Platelet Count Response Defined as Achieving Platelet Counts of at Least 50×10^9/L for at Least 4 of the 6 Visits Between Week 19 and 24 of the Trial.Time frame: From Week 19 up to Week 24

Locations

121 sites in 18 countries. Site status is shown where the registry gives one.

  • Investigator Site 0010038

    Tucson, Arizona

  • Investigator Site 0010045

    Washington D.C., District of Columbia

  • Investigator Site 0010034

    Jacksonville, Florida

  • Investigator site 0010037

    Ocala, Florida

  • Investigator Site 0010042

    Iowa City, Iowa

  • Investigator Site 0010046

    Greenville, North Carolina

  • Investigator Site 0010049

    Cleveland, Ohio

  • Investigator Site 0010040

    Columbus, Ohio

  • Investigator Site 0010041

    Philadelphia, Pennsylvania

  • Investigator Site 0430004

    Linz, Austria

  • Investigator Site 0430002

    Vienna, Austria

  • Investigator Site 0430003

    Vienna, Austria

  • Investigator Site 0320012

    Brasschaat, Belgium

  • Investigator Site 0320011

    Bruges, Belgium

  • Investigator Site 0320015

    Leuven, Belgium

  • Investigator Site 0320014

    Turnhout, Belgium

  • Investigator Site 0320020

    Verviers, Belgium

  • Investigator site 0320002

    Yvoir, Belgium

  • Investigator Site 3590001

    Pleven, Bulgaria

  • Investigator Site 3590002

    Sofia, Bulgaria

  • Investigator Site 4200001

    Brno, Czechia

  • Investigator Site 4200008

    Olomouc, Czechia

  • Investigator Site 4200006

    Ostrava, Czechia

  • Investigator Site 4200007

    Prague, Czechia

  • Investigator Site 0330019

    Clermont-Ferrand, France

  • Investigator Site 0330009

    Créteil, France

  • Investigator Site 0330015

    Le Mans, France

  • Investigator Site 0330018

    Montpellier, France

  • Investigator Site 0330016

    Périgueux, France

  • Investigator Site 0330008

    Pessac, France

  • Investigator Site 0330017

    Rouen, France

  • Investigator Site 9950006

    Tbilisi, Georgia

  • Investigator Site 9950007

    Tbilisi, Georgia

  • Investigator Site 9950008

    Tbilisi, Georgia

  • Investigator Site 9950009

    Tbilisi, Georgia

  • Investigator Site 9950011

    Tbilisi, Georgia

  • Investigator Site 9950012

    Tbilisi, Georgia

  • Investigator Site 0490010

    Düsseldorf, Germany

  • Investigator Site 0490008

    Essen, Germany

  • Investigator Site 0490012

    Giessen, Germany

Showing 40 of 121 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.